Data from Pharmawand - Curated by Marshall Pearce - Date added 07 August 2017

The National Institute for Health and Care Excellence (NICE) in preliminary guidance has decided that Keytruda ( pembrolizumab) from Merck Inc., is not cost effective as a treatment for Urothelial (Bladder) Cancer. NICE accepted that the drug significantly improved overall survival (extension of lives by more than three months) compared to docetexel and paclitaxel chemotherapy but its cost effectiveness is uncertain as its economic modelling is unclear. A final determination will be made in November.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Prostate Cancer

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 5 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Related Content